A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

被引：0

作者：

Riely, Gregory J. ^{[1
]}

Smit, Egbert F. ^{[2
]}

Ahn, Myung-Ju ^{[3
]}

Felip, Enriqueta ^{[4
]}

Ramalingam, Suresh S. ^{[5
]}

Tsao, Anne ^{[6
]}

Johnson, Melissa ^{[7
]}

Gelsomino, Francesco ^{[8
]}

Esper, Raymond ^{[9
]}

Nadal, Ernest ^{[10
]}

Offin, Michael ^{[1
]}

Provencio, Mariano ^{[11
]}

Clarke, Jeffrey ^{[12
]}

Hussein, Maen ^{[9
]}

Otterson, Gregory A. ^{[13
]}

Dagogo-Jack, Ibiayi ^{[14
]}

Goldman, Jonathan W. ^{[15
]}

Morgensztern, Daniel ^{[16
]}

Alcasid, Ann ^{[17
]}

Usari, Tiziana ^{[18
]}

Wissel, Paul ^{[19
]}

Wilner, Keith ^{[20
]}

Pathan, Nuzhat ^{[20
]}

Tonkovyd, Svitlana ^{[21
]}

Johnson, Bruce E. ^{[22
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA

[2] Leiden Univ Med Ctr, Dept Pulm Dis, Leiden, Netherlands

[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[4] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[5] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[6] MD Anderson Canc Ctr, Houston, TX USA

[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[8] IRCCS Azienda Osped Univ Bologna, Med Oncol Unit, I-40138 Bologna, Italy

[9] Florida Canc Specialists, Ft Myers, FL USA

[10] Catalan Inst Oncol, Med Oncol, Barcelona, Spain

[11] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain

[12] Duke Canc Ctr, Durham, NC USA

[13] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[14] Massachusetts Gen Hosp, Boston, MA USA

[15] Univ Calif Los Angeles, Los Angeles, CA USA

[16] Washington Univ, Sch Med, St Louis, MO USA

[17] Pfizer, Collegeville, PA USA

[18] Pfizer, Milan, Italy

[19] Pfizer, New York, NY USA

[20] Pfizer, La Jolla, CA USA

[21] Pfizer, Warsaw, Poland

[22] Dana Farber Canc Inst, Boston, MA USA

来源：

FUTURE ONCOLOGY | 2024年 / 20卷 / 16期

关键词：

encorafenib plus binimetinib; non-small cell lung cancer; PHAROS; plain language summary;

D O I：

10.2217/fon-2023-0859

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

What is this summary about? This is a summary of the results of a study called PHAROS. This study looked at combination treatment with encorafenib (BRAFTOVI (R)) and binimetinib (MEKTOVI (R)). This combination of medicines was studied in people with metastatic non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Metastatic means that the cancer has spread to other parts of the body. All people in this study had a type of NSCLC that has a change in a gene called BRAF termed a BRAF V600E mutation. A gene is a part of the DNA that has instructions for making things that your body needs to work, and the BRAF V600E mutation contributes to the growth of the lung cancer. What were the results? In this study, 98 people with BRAF V600E-mutant metastatic NSCLC were treated with the combination of encorafenib and binimetinib (called encorafenib plus binimetinib in this summary). Before starting the study, 59 people had not received any treatment for their metastatic NSCLC, and 39 people had received previous anticancer treatment. At the time of this analysis, 44 (75%) out of 59 people who did not receive any treatment before taking encorafenib plus binimetinib had their tumors shrink or disappear. Eighteen (46%) out of 39 people who had received treatment before starting encorafenib plus binimetinib also had their tumors shrink or disappear. The most common side effects of encorafenib plus binimetinib were nausea, diarrhea, fatigue, and vomiting. What do the results mean? These results support the use of encorafenib plus binimetinib combination treatment as a new treatment option in people with BRAF V600E-mutant metastatic NSCLC. The side effects of encorafenib plus binimetinib in this study were similar to the side effects seen with encorafenib plus binimetinib in people with a type of skin cancer called metastatic melanoma.

引用

页码：1047 / 1055

页数：9